Trial
NCT00883116
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
R-Pharm
Collaborators
—
Condition
Endometrial Cancer
Intervention
Ixabepilone
Why stopped
Interim analysis results showed that ixabepilone did not improve survival compared with control chemotherapies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-09